SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 DiabetesGlobeNewsWire • 01/10/23
SAB Biotherapeutics' CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech ShowcaseGlobeNewsWire • 01/09/23
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune DiseasesGlobeNewsWire • 01/05/23
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San FranciscoGlobeNewsWire • 12/15/22
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 DiabetesGlobeNewsWire • 11/21/22
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases' at U.S. Pharma Partnering Summit 2022GlobeNewsWire • 11/08/22
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology ConferenceGlobeNewsWire • 11/03/22
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutionsGlobeNewsWire • 10/27/22
SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185's Effectiveness Against Multiple COVID-19 VariantsGlobeNewsWire • 09/23/22
SAB Biotherapeutics, Inc. (SABS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 08/24/22
SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds DownGlobeNewsWire • 08/09/22
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical OfficerGlobeNewsWire • 06/06/22
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering SummitGlobeNewsWire • 05/31/22
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/12/22
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company's Board of Scientific AdvisorsGlobeNewsWire • 04/05/22
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial ResultsGlobeNewsWire • 03/29/22
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID HospitalizationsGlobeNewsWire • 03/02/22
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 VariantsGlobeNewsWire • 03/02/22
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19GlobeNewsWire • 02/25/22